Bio News
Swiss drugmaker Novartis said remibrutinib outperformed Aubagio in reducing annualized relapse rates and inflammatory brain lesions in two phase 3 trials involving patients with relapsing multiple sclerosis (MS). Novartis said remibrutinib had a clinically meaningful effect on disability progression and did not produce the liver-related adverse effects that have been an issue with other BTK inhibitors in the same class. Novartis plans to share the study results with health authorities, and the company’s shares rose more than 4% that day.
Biobook Team
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
